Wound Mgmt Tech (WNDM) 0.0880 $WNDM
Wound Management Technologies Announces Its 2014 Annual Meeting of Shareholders
Marketwire - Tue Aug 26, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(R), announced that its 2014 Annual Meeting of Shareholders will be held at the Company's corporate offices located at 16633 Dallas Parkway, Suite 250 in Addison, TX on September 3, 2014 at 10AM CST.
Wound Management Technologies Launches Risk-Sharing Program to Reimburse Hospitals for Certain SSI Costs to Highlight Effectiveness of CellerateRX(r) Surgical
ACCESSWIRE - Tue Aug 19, 7:31AM CDT
Addison, TEXAS / ACCESSWIRE / August 19, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced that its Wound Care Innovations subsidiary has launched the CellerateRX(r) Surgical Assurance Program, a risk-sharing program to help hospitals and surgical centers lower the uncompensated care costs associated with readmissions due to surgical site infections (SSIs).
Wound Management Technologies Reports Financial Results for the Second Quarter Ended June 30, 2014
ACCESSWIRE - Thu Aug 14, 3:06PM CDT
Addison, TX / ACCESSWIRE / August 14, 2014 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced its financial and operating results for the three month period ended on June 30, 2014.
Wound Management Technologies, Inc. Retains KCSA Strategic Communications as U.S. Investor Relations Counsel
ACCESSWIRE - Thu Jul 31, 10:52AM CDT
Addison, TEXAS / ACCESSWIRE / July 31, 2014 / Wound Management Technologies, Inc. (OTC BB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA- approved collagen product, CellerateRX(R), today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to lead the Company's investor relations program.
Markets for Advanced Wound Management Technologies
PR Newswire - Thu Jun 19, 6:51AM CDT
Reportlinker.com announces that a new market research report is available in its catalogue:
Wound Management Technologies Announces Jane Fore, MD as Chief Medical Officer and Dr. Alec Hochstein as Medical Director
ACCESSWIRE - Wed Mar 19, 8:41AM CDT
ADDISON, TX / ACCESSWIRE / March 19, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM), announced today that Dr. Jane Fore is the new Chief Medical Officer for the Wound Care Innovations Subsidiary and Dr. Alec Hochstein has joined the company as Medical Director. Both are actively involved in the CellerateRX(R) Activated Collagen product line.
Wound Management Technologies Adds CFO and Director of Research and Development
ACCESSWIRE - Mon Mar 17, 3:11PM CDT
ADDISON, TX / ACCESSWIRE / March 17, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) has engaged Mr. Darren Stine as the Company's new Chief Financial Officer and Mr. Barry Constantine has agreed to expand his role within the Company as its new Director of Research and Development.
Wound Managements' Subsidiary, Resorbable Orthopedic Products, Announces BioStructures has FDA 510(k) Clearance for Innovative Bioactive Bone Graft Putty and Bone Graft Extender; Commercial License Granted
ACCESSWIRE - Tue Feb 18, 7:36AM CST
ADDISON, TX - (ACCESSWIRE - February 18, 2014) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that its subsidiary, Resorbable Orthopedic Products, LLC, has granted a commercial license to BioStructures, LLC to market their newly FDA 510(k) cleared Bioactive Bone Graft Putty (Signafuse™). BioStructures developed this product under the Development and License Agreement with ROP that was announced on November 11, 2011 under which BioStructures combined their proprietary biomaterials with ROP's patented resorbable wax carrier. This license creates Resorbable Orthopedic Products first revenue stream.
Wound Management Technologies Inc. Receives Financing from Key Shareholder Group; Turns Focus to Strategic Growth
ACCESSWIRE - Wed Dec 18, 8:17AM CST
ADDISON, TX - (Accesswire - December 18, 2013) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that it has received a financing commitment from existing shareholders to invest an additional $2.4 million in Series C preferred shares and to convert over $1.5 M of existing debt to the Series C preferred shares. The financing subscription documents have been received and the commitment will be fully funded by February 28, 2014. The Board of Directors unanimously supported this action and authorized a $3 M extension to the Series C offering.
CellerateRX(R) Reports Significant Second Quarter and Annual Sales Increase
Marketwire - Mon Aug 26, 8:47AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announces an increase in sales of CellerateRX(R) for the second quarter, ending June 2013 up 54% over the same period in 2012. Sales year to date have risen 111% over year to date sales in 2012. Robert Lutz Jr., chief executive officer, commented, "We attribute our growing success to increased use of CellerateRx for surgical wounds in hospitals and increased use in the woundcare marketplace." Lutz added, "We will continue to expand our sales and distribution efforts with hospitals, woundcare centers, and the longterm care and hospice market places adding new accounts based on the strong efficacy of the product."
Wound Management Technologies Enters Into Distribution Agreement With Academy Medical
Marketwire - Mon Jul 08, 3:30PM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announced it has entered into a distribution agreement with Academy Medical, LLC, a veteran-owned distributor of medical products, to sell its CellerateRX line of products to the VA facilities across the country. The Veterans Administration system represents over 168 Hospitals, 1700 "sites of care" facilities and 8.3 million veterans. The agreement has a term of five years and minimum purchase amounts from Wound Management of $600,000 and 1.5 million the first two years growing to $3 million by year five of the contract.
Wound Management Technologies 2012 Sales Strategy Shows Positive Results; Receives Final Resolution with SEC
PR Newswire - Tue Feb 05, 9:30AM CST
WOUND MANAGEMENT TECHNOLOGIES (OTCQB: WNDM | WNDM.PK) finished 2012 with fourth quarter customer sales revenues of approximately $440,000 (an increase of 23% over the previous quarter) and annual sales revenues of approximately $1.18M. In May of 2012 the Company announced it had completed a new three-year strategic plan that focuses on CellerateRX® customer sales and that a new surgical product would be introduced in 2012. In October 2012 the Company announced positive results for the new CellerateRX® surgical products. "Clearly our plan and our team's efforts are yielding results," stated Robert H. Lutz, Jr., Chairman and CEO of the company. "We expect the upward sales trend to continue throughout 2013 and beyond."
Wound Management Technologies Announces Its 2014 Annual Meeting of Shareholders
Marketwire - Tue Aug 26, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(R), announced that its 2014 Annual Meeting of Shareholders will be held at the Company's corporate offices located at 16633 Dallas Parkway, Suite 250 in Addison, TX on September 3, 2014 at 10AM CST.
Wound Management Technologies Launches Risk-Sharing Program to Reimburse Hospitals for Certain SSI Costs to Highlight Effectiveness of CellerateRX(r) Surgical
ACCESSWIRE - Tue Aug 19, 7:31AM CDT
Addison, TEXAS / ACCESSWIRE / August 19, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced that its Wound Care Innovations subsidiary has launched the CellerateRX(r) Surgical Assurance Program, a risk-sharing program to help hospitals and surgical centers lower the uncompensated care costs associated with readmissions due to surgical site infections (SSIs).
Wound Management Technologies Reports Financial Results for the Second Quarter Ended June 30, 2014
ACCESSWIRE - Thu Aug 14, 3:06PM CDT
Addison, TX / ACCESSWIRE / August 14, 2014 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced its financial and operating results for the three month period ended on June 30, 2014.
Wound Management Technologies, Inc. Retains KCSA Strategic Communications as U.S. Investor Relations Counsel
ACCESSWIRE - Thu Jul 31, 10:52AM CDT
Addison, TEXAS / ACCESSWIRE / July 31, 2014 / Wound Management Technologies, Inc. (OTC BB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA- approved collagen product, CellerateRX(R), today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to lead the Company's investor relations program.
Markets for Advanced Wound Management Technologies
PR Newswire - Thu Jun 19, 6:51AM CDT
Reportlinker.com announces that a new market research report is available in its catalogue:
Wound Management Technologies Announces Jane Fore, MD as Chief Medical Officer and Dr. Alec Hochstein as Medical Director
ACCESSWIRE - Wed Mar 19, 8:41AM CDT
ADDISON, TX / ACCESSWIRE / March 19, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM), announced today that Dr. Jane Fore is the new Chief Medical Officer for the Wound Care Innovations Subsidiary and Dr. Alec Hochstein has joined the company as Medical Director. Both are actively involved in the CellerateRX(R) Activated Collagen product line.
Wound Management Technologies Adds CFO and Director of Research and Development
ACCESSWIRE - Mon Mar 17, 3:11PM CDT
ADDISON, TX / ACCESSWIRE / March 17, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) has engaged Mr. Darren Stine as the Company's new Chief Financial Officer and Mr. Barry Constantine has agreed to expand his role within the Company as its new Director of Research and Development.
Wound Managements' Subsidiary, Resorbable Orthopedic Products, Announces BioStructures has FDA 510(k) Clearance for Innovative Bioactive Bone Graft Putty and Bone Graft Extender; Commercial License Granted
ACCESSWIRE - Tue Feb 18, 7:36AM CST
ADDISON, TX - (ACCESSWIRE - February 18, 2014) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that its subsidiary, Resorbable Orthopedic Products, LLC, has granted a commercial license to BioStructures, LLC to market their newly FDA 510(k) cleared Bioactive Bone Graft Putty (Signafuse™). BioStructures developed this product under the Development and License Agreement with ROP that was announced on November 11, 2011 under which BioStructures combined their proprietary biomaterials with ROP's patented resorbable wax carrier. This license creates Resorbable Orthopedic Products first revenue stream.
Wound Management Technologies Inc. Receives Financing from Key Shareholder Group; Turns Focus to Strategic Growth
ACCESSWIRE - Wed Dec 18, 8:17AM CST
ADDISON, TX - (Accesswire - December 18, 2013) - Wound Management Technologies, Inc., (OTCQB: WNDM) announced today that it has received a financing commitment from existing shareholders to invest an additional $2.4 million in Series C preferred shares and to convert over $1.5 M of existing debt to the Series C preferred shares. The financing subscription documents have been received and the commitment will be fully funded by February 28, 2014. The Board of Directors unanimously supported this action and authorized a $3 M extension to the Series C offering.
CellerateRX(R) Reports Significant Second Quarter and Annual Sales Increase
Marketwire - Mon Aug 26, 8:47AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announces an increase in sales of CellerateRX(R) for the second quarter, ending June 2013 up 54% over the same period in 2012. Sales year to date have risen 111% over year to date sales in 2012. Robert Lutz Jr., chief executive officer, commented, "We attribute our growing success to increased use of CellerateRx for surgical wounds in hospitals and increased use in the woundcare marketplace." Lutz added, "We will continue to expand our sales and distribution efforts with hospitals, woundcare centers, and the longterm care and hospice market places adding new accounts based on the strong efficacy of the product."
Wound Management Technologies Enters Into Distribution Agreement With Academy Medical
Marketwire - Mon Jul 08, 3:30PM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM) announced it has entered into a distribution agreement with Academy Medical, LLC, a veteran-owned distributor of medical products, to sell its CellerateRX line of products to the VA facilities across the country. The Veterans Administration system represents over 168 Hospitals, 1700 "sites of care" facilities and 8.3 million veterans. The agreement has a term of five years and minimum purchase amounts from Wound Management of $600,000 and 1.5 million the first two years growing to $3 million by year five of the contract.
Wound Management Technologies 2012 Sales Strategy Shows Positive Results; Receives Final Resolution with SEC
PR Newswire - Tue Feb 05, 9:30AM CST
WOUND MANAGEMENT TECHNOLOGIES (OTCQB: WNDM | WNDM.PK) finished 2012 with fourth quarter customer sales revenues of approximately $440,000 (an increase of 23% over the previous quarter) and annual sales revenues of approximately $1.18M. In May of 2012 the Company announced it had completed a new three-year strategic plan that focuses on CellerateRX® customer sales and that a new surgical product would be introduced in 2012. In October 2012 the Company announced positive results for the new CellerateRX® surgical products. "Clearly our plan and our team's efforts are yielding results," stated Robert H. Lutz, Jr., Chairman and CEO of the company. "We expect the upward sales trend to continue throughout 2013 and beyond."
